

Publications

Ascone L, Rohenkohl AC, Hurlmann R, Meisenzahl E, Riedel-Heller SG, Becker T, Bajbouj M, von Lilienfeld-Toal M, Gallinat J, Lambert M (2023) [Assessment of direct (COVID-19-Related) and collateral, psychosocial pandemic consequences for vulnerable groups by the example of serious mental illness]. *Psychiatr Prax* 50(7), 381-388.

Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, Navarro D, von Lilienfeld-Toal M, Mehra V, Marchesi F, Besson C, Masculano RC, Beutel G, Einsele H, Maertens J, de la Camara R, Ljungman P, Pagano L (2023) Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). *Leukemia* 37(9), 1933-1938.

Giesen N, Busch E, Schalk E, Beutel G, Rührich MM, Hentrich M, Hertenstein B, Hirsch HH, Karthaus M, Khodamoradi Y, Koehler P, Krüger W, Koldehoff M, Krause R, Mellinghoff SC, Penack O, Sandherr M, Seggewiss-Bernhardt R, Spiekermann K, Sprute R, Stemler J, Weissinger F, Wörmann B, Wolf HH, Cornely OA, Rieger CT, von Lilienfeld-Toal M (2023) AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. *Eur J Cancer* 181, 102-118. (Review)

Goldmann M^{*}, Schmidt F^{*}, Cseresnyés Z, Orasch T, Jahreis S, Hartung S, Figge MT, von Lilienfeld-Toal M, Heinekamp T, Brakhage AA[#] (2023) The lipid raft-associated protein stomatin is required for accumulation of dectin-1 in the phagosomal membrane and for full activity of macrophages against *Aspergillus fumigatus*. *mSphere* 8(1), e00523-22.

Steinbeis F, Thibeault C, Steinbrecher S, Ahlgrimm Y, Haack IA, August D, Balzuweit B, Bellinghausen C, Berger S, Chaplinskaya-Sobol I, Cornely O, Doeblin P, Endres M, Fink C, Finke C, Frank S, Hanß S, Hartung T, Hellmuth JC, Herold S, Heuschmann P, Heyckendorf J, Heyder R, Hippenstiel S, Hoffmann W, Kelle SU, Knape P, Koehler P, Kretzler L, Leistner DM, Lienau J, Lorbeer R, Lorenz-Depiereux B, Lüttke CD, Mai K, Merle U, Meyer-Arndt LA, Miljukov O, Muenchhoff M, Müller-Plathe M, Neuhaus J, Neuhauser H, Nieters A, Otte C, Pape D, Pinto RM, Pley C, Pudszuhn A, Reuken P, Rieg S, Ritter P, Rohde G, Rönnefarth M, Ruzicka M, Schaller J, Schmidt A, Schmidt S, Schwachmeyer V, Schwanitz G, Seeger W, Stahl D, Stobäus N, Stubbe HC, Suttorp N, Temmesfeld B, Thun S, Triller P, Trinkmann F, Vadasz I, Valentin H, Vehreschild M, von Kalle C, von Lilienfeld-Toal M, Weber J, Welte T, Wildberg C, Wizimirski R, Zvork S, Sander LE, Vehreschild J, Zoller T, Kurth F, Witzentrath M (2023) Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP). *Infection* 52(1), 93-104.

Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wörmann B, Turajlic S, von Lilienfeld-Toal M (2022) COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. *Nat Rev Clin Oncol* 19(6), 385-401. (Review)

Hoang TNM^{*}, Cseresnyés Z^{*}, Hartung S^{*}, Blickensdorf M, Saffer C, Rennert K, Mosig AS, von Lilienfeld-Toal M, Figge MT (2022) Invasive aspergillosis-on-chip: A quantitative treatment study of human *Aspergillus fumigatus* infection. *Biomaterials* 283, 121420.

Montaño DE, Hartung S, Wich M, Ali R, Jungnickel B, von Lilienfeld-Toal M, Voigt K (2022) The TLR-NF-κB axis contributes to the monocytic inflammatory response against a virulent strain

of *Lichtheimia corymbifera*, a causative agent of invasive mucormycosis. *Front Immunol* 13, 882921.

Böttcher S, Hartung S, Meyer F, Rummler S, Voigt K, Walther G, Hochhaus A, von Lilienfeld-Toal M, Jahreis S (2021) Human mucosal-associated invariant T cells respond to Mucorales species in a MR1-dependent manner. *Med Mycol* 59(5), 505-509.

Giesen N, Sprute R, Rüttrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M (2021) Evidence-based management of COVID-19 in cancer patients: Guideline by the infectious diseases working party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). *Eur J Cancer* 140, 86-104.

Roth M, Holtmann C, Daas L, Kakkassery V, Kurzai O, Geerling G, Bäurle S, Bayoudh W, Brücher V, Cvetkova-Fischer N, Dias Blak M, Bornstein A, Fischer C, Fuest M, Grisanti S, Herwig-Carl M, Kroll S, Lenk J, Lommatzsch C, MacKenzie C, Matthaei M, Mehlan J, Messmer E, Müller V, Pawlik V, Ranjbar M, Renner-Wilde A, Rickmann A, Saeger M, Schargus M, Schwarz L, Seitz B, Steindor F, Unterlauf JD, Viestenz A, von Lilienfeld-Toal M, Walther G (2021) Results from the German fungal keratitis registry: Significant differences between cases with and without a history of contact lens use. *Cornea* 40(11), 1453-1461.

Rüttrich MM, Giessen-Jung C, Borgmann S, Classen AY, Dolff S, Grüner B, Hanses F, Isberner N, Köhler P, Lanznaster J, Merle U, Nadalin S, Piepel C, Schneider J, Schons M, Strauss R, Tometten L, Vehreschild JJ, von Lilienfeld-Toal M, Beutel G, Wille K (2021) COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. *Ann Hematol* 100(2), 383-393.

Walther G, Zimmermann A, Theuersbacher J, Kaerger K, von Lilienfeld-Toal M, Roth M, Kampik D, Geerling G, Kurzai O (2021) Eye infections caused by filamentous fungi: Spectrum and antifungal susceptibility of the prevailing agents in Germany. *J Fungi (Basel)* 7(7), 511.

Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO (2020) Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). *J Cancer Res Clin Oncol* 146(3), 749-759.

Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH (2020) Frequency of infections in 948 MPN patients: A prospective multicenter patient-reported pilot study. *Leukemia* 34(7), 1949-1953.

Mayer K, Hahn-Ast C, Schwab K, Schmidt-Wolf IGH, Brossart P, Glasmacher A, von Lilienfeld-Toal M (2020) Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review. *Eur J Haematol* 104(6), 538-545. (Review)

Mian H, Grant SJ, Engelhardt M, Pawlyn C, Bringhen S, Zweegman S, Stege CAM, Rosko AE, von Lilienfeld-Toal M, Wildes TM (2020) Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the international forum for optimizing care of older adults with myeloma. *J Geriatr Oncol* 11(5), 764-768.

Rachow T, Lamik T, Kalkreuth J, Kurze S, Wagner K, Stier P, Hammersen FJ, Rüttrich MM, Winkelmann N, Klink A, Hilgendorf I, Hermann B, Lang S, Hochhaus A, von Lilienfeld-Toal M (2020) Detection of community-acquired respiratory viruses in allogeneic stem-cell transplant recipients and controls-A prospective cohort study. *Transpl Infect Dis* 22(6), e13415.

Ruhnke M, Cornely OA, Schmidt-Hieber M, Alakel N, Boell B, Buchheidt D, Christopeit M, Hasenkamp J, Heinz WJ, Hentrich M, Karthaus M, Koldehoff M, Maschmeyer G, Panse J, Penack O, Schleicher J, Teschner D, Ullmann AJ, Vehreschild M, von Lilienfeld-Toal M, Weissinger F, Schwartz S (2020) Treatment of invasive fungal diseases in cancer patients-Revised 2019 recommendations of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Mycoses* 63(7), 653-682.

Shopova IA, Belyaev I, Dasari P, Jahreis S, Stroe MC, Cseresnyés Z, Zimmermann AK, Medyukhina A, Svensson C-M, Krüger T, Szeifert V, Nietzsche S, Conrad T, Blango MG, Kniemeyer O, von Lilienfeld-Toal M, Zipfel PF, Ligeti E, Figge MT, Brakhage AA (2020) Human neutrophils produce antifungal extracellular vesicles against *Aspergillus fumigatus*. *mBio* 11(2), e00596-20.

von Lilienfeld-Toal M (2020) Community-acquired respiratory viruses in oncology: Lessons to be learnt from the SARS-CoV-2 pandemic. *Oncol Res Treat* 43(6), 262-263.

von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F, Hirsch HH (2020) Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. *Leukemia* 34(6), 1487-1494. (Review)

Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, Scherag A, Yomade O, Schilling K, Hochhaus A, Mügge LO, von Lilienfeld-Toal M (2019) The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. *Ann Hematol* 98(3), 713-722.

Dimitriou V, Biehl LM, Hamprecht A, Vogel W, Dörfel D, Peter S, Schafhausen P, Rohde H, von Lilienfeld-Toal M, Klassert TE, Slickers P, Ehrlich R, Slevogt H, Christ H, Hellmich M, Farowski F, Tsakmaklis A, Higgins PG, Seifert H, Vehreschild MJGT (2019) Controlling intestinal colonization of high-risk haematology patients with ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled, multicentre, Phase II trial (CLEAR). *J Antimicrob Chemother* 74(7), 2065-2074.

Hartung S, Rauh C, Boettcher S, Hoang MTN, Jahreis S, Rummler S, Hochhaus A, von Lilienfeld-Toal M (2019) Measuring phagocytosis of *Aspergillus fumigatus* conidia by human leukocytes using flow cytometry. *J Vis Exp* (154),

Hartung S, Rauh C, Hoang TNM, Jahreis S, Wagner K, Macheleidt J, Brakhage AA, Rummler S, Hochhaus A, von Lilienfeld-Toal M (2019) Fast and quantitative evaluation of human leukocyte interaction with *Aspergillus fumigatus* conidia by flow cytometry. *Cytometry A* 95(3), 332-338.

Hütter-Krönke ML, Fiedler W, Kündgen A, Krauter J, von Lilienfeld-Toal M, Döhner H, Schlenk RF (2019) Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. *Haematologica* 104(2), e63-e64.

Jahreis S, Boettcher S, von Lilienfeld-Toal M (2019) MAIT cell activation by fungal pathogens. *Methods Mol Biol* 2098, 167-177.

Kochanek M, Schalk E, von Bergwelt-Baildon M, Beutel G, Buchheidt D, Hentrich M, Henze L, Kiehl M, Liebrechts T, von Lilienfeld-Toal M, Classen A, Mellinghoff S, Penack O, Piepel C, Böll B (2019) Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Hematol* 98(5), 1051-1069.

Roth M, Daas L, Renner-Wilde A, Cvetkova-Fischer N, Saeger M, Herwig-Carl M, Matthaei M, Fekete A, Kakkassery V, Walther G, von Lilienfeld-Toal M, Mertens C, Lenk J, Mehlan J, Fischer C, Fuest M, Kroll S, Bayouh W, Viestenz A, Frings A, MacKenzie CR, Messmer EM, Seitz B, Kurzai O, Geerling G (2019) Das Deutsche Pilz-Keratitis-Register: Erste Ergebnisse einer multizentrischen Erhebung [The German keratomycosis registry: Initial results of a multicenter survey]. *Ophthalmologie* 116(10), 957-966.

von Lilienfeld-Toal M, Wagener J, Einsele H, Cornely OA, Kurzai O (2019) Invasive fungal infection. *Dtsch Arztebl Int* 116(16), 271-278. (Review)

Wagner-Drouet E, Teschner D, Wolschke C, Janson D, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Kondakci M, Hilgendorf I, von Lilienfeld-Toal M, Klein S, Heidenreich D, Kreil S, Verbeek M, Graß S, Ditschkowski M, Gromke T, Koch M, Lindemann M, Hünig T, Schmidt T, Rasche A, Guldán H, Barabas S, Deml L, Wagner R, Wolff D (2019) Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. *Haematologica* [Epub ahead of print]

Jahreis S, Böttcher S, Hartung S, Rachow T, Rummeler S, Dietl AM, Haas H, Walther G, Hochhaus A, von Lilienfeld-Toal M (2018) Human MAIT cells are rapidly activated by *Aspergillus* spp. in an APC-dependent manner. *Eur J Immunol* 48(10), 1698-1706.

Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, Heinz WJ, Hentrich M, Maschmeyer G, Mayer K, Sandherr M, Silling G, Ullmann A, Vehreschild MJGT, von Lilienfeld-Toal M, Wolf HH, Lehnert N (2018) Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). *Ann Oncol* 29(6), 1354-1365.

Ruhnke M, Behre G, Buchheidt D, Christopeit M, Hamprecht A, Heinz W, Heussel CP, Horger M, Kurzai O, Karthaus M, Löffler J, Maschmeyer G, Penack O, Rieger C, Rickerts V, Ritter J, Schmidt-Hieber M, Schuelper N, Schwartz S, Ullmann A, Vehreschild JJ, von Lilienfeld-Toal M, Weber T, Wolf HH (2018) Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). *Mycoses* 61(11), 796-813. (Review)

von Lilienfeld-Toal M, Maschmeyer G (2018) Challenges in infectious diseases for haematologists. *Oncol Res Treat* 41(6), 406-410.

Biehl LM, Bertz H, Bogner J, Dobermann UH, Kessel J, Krämer C, Lemmen S, von Lilienfeld-Toal M, Peter S, Pletz MW, Rohde H, Schmiedel S, Schubert S, Ullmann AJ, Fätkenheuer G, Vehreschild MJGT (2017) Screening and contact precautions - A survey on infection control measures for multidrug-resistant bacteria in German university hospitals. *Antimicrob Resist Infect Control* 6, 37.

Brioli A, Mügge LO, Hochhaus A, Von Lilienfeld-Toal M (2017) Safety issues and management of

toxicities associated with new treatments for multiple myeloma. *Expert Rev Hematol* 10(3), 193-205. (Review)

Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild JJ, Weissinger F, Maschmeyer G (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Ann Hematol* 96(11), 1775-1792.

Hermann B, Lehnert N, Brodhun M, Boden K, Hochhaus A, Kochanek M, Meckel K, Mayer K, Rachow T, Rieger C, Schalk E, Weber T, Schmeier-Jürchott A, Schlattmann P, Teschner D, von Lilienfeld-Toal M (2017) Influenza virus infections in patients with malignancies -- characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). *Eur J Clin Microbiol Infect Dis* 36(3), 565-573.

Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehnert N, von Lilienfeld-Toal M, Löhnert AY, Maschmeyer G, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA (2017) Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology. *Ann Hematol* [Epub ahead of print]

Rachow T, Schlüter V, Bremer-Streck S, Lindig U, Scholl S, Schlattmann P, Kiehnkopf M, Hochhaus A, von Lilienfeld-Toal M (2017) Measurement of piperacillin plasma concentrations in cancer patients with suspected infection. *Infection* 45(5), 629-636.

Walther G, Stasch S, Kaerger K, Hamprecht A, Roth M, Cornely OA, Geerling G, Mackenzie CR, Kurzai O, von Lilienfeld-Toal M (2017) Fusarium Keratitis in Germany. *J Clin Microbiol* 55(10), 2983-2995.

Hahn-Ast C, Felder L, Mayer K, Mückter S, Ruhnke M, Hein R, Hellmich M, Schwab K, Rachow T, Brossart P, von Lilienfeld-Toal M (2016) Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia. *Ann Hematol* 95(6), 1001-1009.

Rachow T, Dornaus S, Sayer HG, Hermann B, Hochhaus A, von Lilienfeld-Toal M (2016) Case report: false positive elevated serum-galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements. *Clin Case Rep.* 4(5), 505-508.

von Lilienfeld-Toal M, Berger A, Christopeit M, Hentrich M, Heussel CP, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf HH, Lehnert N, Schalk E, Mayer K (2016) Community acquired respiratory virus infections in cancer patients- Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. *Eur J Cancer* 67, 200-212.

Mayer K, Hahn-Ast C, Mückter S, Schmitz A, Krause S, Felder L, Bekeredjian-Ding I, Molitor E, Brossart P, von Lilienfeld-Toal M (2015) Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia. *Support Care Cancer* 23(5), 1321-1329.

Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA (2015) Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). *Ann Hematol* 94(9), 1441-1450.

Schnetzke U, Spies-Weisshart B, Yomade O, Fischer M, Rachow T, Schrenk K, Glaser A, von Lilienfeld-Toal M, Hochhaus A, Scholl S (2015) Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia. *Genes Immun* 16(1), 83-88.

Schrenk KG, Schnetzke U, Stegemann K, von Lilienfeld-Toal M, Hochhaus A, Scholl S (2015) Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. *J Cancer Res Clin Oncol* 141(9), 1661-1668.

Busch A, Zeh D, Janzen V, Mügge LO, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal M (2014) Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. *Clin Exp Immunol* 177(2), 439-453.

Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H (2014) Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). *Ann Hematol* 93(7), 1083-1095.

Schwab KS, Hahn-Ast C, Heinz WJ, Germing U, Egerer G, Glasmacher A, Leyendecker C, Marklein G, Nellessen CM, Brossart P, von Lilienfeld-Toal M (2014) Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. *Infection* 42(1), 97-9104.

Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, Cornely OA, Seifert H (2014) A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. *J Antimicrob Chemother* 69(12), 3387-3392.

Feldmann G, Brossart P, von Lilienfeld-Toal M (2013) Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment. *Ann Hematol* 92(11), 1577-1579.

Feldmann G, Brossart P, Zipfel M, von Lilienfeld-Toal M (2013) Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature. *Case Rep Oncol* 6(1), 229-235.

Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brügger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K (2013) Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AML5SG). *Blood* 121(23), 4769-4777.

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G,

Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med* 369(2), 111-121.

Mayer K, Kapelle M, Kaefenstein A, Weßling M, Bekeredjian-Ding I, Leutner C, von Lilienfeld-Toal M, Brossart P, Wolf D (2013) Successful management of *Candida krusei* monoarthritis after allo-SCT. *Bone Marrow Transplant* 48(12), 1585-1586.

Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M (2013) Primary prophylaxis of bacterial infections and *Pneumocystis jirovecii* pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the DGHO. *Ann Hematol* 92(4), 433-442.

Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Späth D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Köhne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Götze K, Horst HA, Ringhoffer M, Lübbert M, Wattad M, Salih HR, Kündgen A, Döhner H, Döhner K (2013) Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSSG). *Blood* 121(1), 170-177.

Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C (2012) Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. *Ann Hematol* 91(1), 47-55.

Fleischhacker M, Schulz S, Jöhrens K, von Lilienfeld-Toal M, Held T, Fietze E, Schewe C, Petersen I, Ruhnke M (2012) Diagnosis of chronic disseminated candidosis from liver biopsies by a novel PCR in patients with haematological malignancies. *Clin Microbiol Infect* 18(10), 1010-1016.

Gaidzik VI, Paschka P, Späth D, Habdank M, Köhne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L, Döhner K (2012) TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. *J Clin Oncol* 30(12), 1350-1357.

Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H, Schlenk RF (2012) Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. *Blood* 119(2), 551-558.

Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübbert M, Fröhling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. *Blood* 119(9), 2114-2121.

Wolf D, von Lilienfeld-Toal M, Wolf AM, Schleuning M, von Bergwelt-Baildon M, Held SA, Brossart P (2012) Novel treatment concepts for graft-versus-host disease. *Blood* 119(1), 16-25.

Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C,

Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N (2011) Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. *Bone Marrow Transplant* 46(8), 1045-1052.

Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. *Blood* 117(7), 2137-2145.

Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. *J Clin Oncol* 29(19), 2709-2716.

Penack O, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Massenkeil G, Hentrich M, Salwender H, Wolf HH, Ostermann H (2011) Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. *Ann Oncol* 22(5), 1019-1029.

Vehreschild MJ, Meissner AM, Cornely OA, Maschmeyer G, Neumann S, von Lilienfeld-Toal M, Karthaus M, Wattad M, Staib P, Hellmich M, Christ H, Vehreschild JJ (2011) Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. *Haematologica* 96(12), 1855-1860.

*equal contribution #corresponding author